New cocktail therapy targets rare cancer after standard treatment fails
NCT ID NCT07518602
First seen Apr 10, 2026 · Last updated Jun 19, 2026 · Updated 15 times
Summary
This phase 2 trial tests a combination of three drugs—chidamide, sintilimab, and bevacizumab—in 34 people with advanced extrapulmonary neuroendocrine carcinoma that has worsened after first-line therapy. The goal is to see if this combo can shrink tumors or slow disease progression. Participants receive the drugs orally and intravenously over several weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Chidamide (oral drug), Sintilimab (immunotherapy), Bevacizumab (anti-angiogenic drug)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced extrapulmonary neuroendocrine carcinoma who have run out of standard options.
What could go wrong
This is a small, early-phase trial (34 people) with no control group, so results may not be definitive. The drug combination may cause side effects like immune-related reactions or bleeding risks.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.